MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
52.86%
Quick Ratio
52.86%
Cash Ratio
39.55%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Restricted cash
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid-in capital
    • Advances from collaboration part...
    • Others

Balance Sheets
2026-03-31
Cash and cash equivalents
6,363
Restricted cash
6
Prepaid expenses and other current assets
2,134
Total current assets
8,503
Total assets
8,503
Accounts payable
3,028
Accrued expenses
1,236
Advances from collaboration partners, net of debt discount
11,823
Current portion of long-term debt
0
Accrued interest on debt
0
Total current liabilities
16,087
Common stock, 0.01 par value per share, 500,000,000 shares authorized, 5,072,935 and 4,790,239 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively
51
Additional paid-in capital
296,699
Accumulated deficit
-304,334
Total stockholders' deficit
-7,584
Total liabilities and stockholders' deficit
8,503
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$6,363K Prepaid expenses andother current assets$2,134K Restricted cash$6K Total current assets$8,503K Total assets$8,503K Accumulated deficit-$304,334K Total liabilities andstockholders' deficit$8,503K Total stockholders'deficit-$7,584K Additional paid-in capital$296,699K Common stock, 0.01 parvalue per share,...$51K Total currentliabilities$16,087K Advances fromcollaboration partners, net of...$11,823K Accounts payable$3,028K Accrued expenses$1,236K

Eloxx Pharmaceuticals, Inc. (ELOX)

Eloxx Pharmaceuticals, Inc. (ELOX)